TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20602795

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimanual occupational therapy
Number of subjects: 0
Study: 17580357

Group type: EXPERIMENTAL
Intervention: duloxetine 80 mg/day
Number of subjects: 588

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 588
Study: 15644669

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 7.5% saline/6% dextran solution (HSD)
Number of subjects: 9
Study: 12064330

Group type: COMPARATOR
Intervention: 0.8 mg/d phylloquinone for 12 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2.0 mg/d phylloquinone for 12 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4.0 mg/d phylloquinone for 12 days
Number of subjects: 31
Study: 10571498

Group type: EXPERIMENTAL
Intervention: Handgrip test
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Passive 80 degrees head-up tilt
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Heart rate responsiveness
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control participants (age- and sex-matched)
Number of subjects: 33
Study: 7845827

Group type: EXPERIMENTAL
Intervention: Propafenone (600 mg)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Digoxin (1 mg)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 2902491

Group type: EXPERIMENTAL
Intervention: Urgent endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy (ES)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 121
Study: 31676910

Group type: EXPERIMENTAL
Intervention: Checking‐in (Graduated extinction protocol)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Camping‐out (Parental presence maintained)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 91
Study: 29448399

Group type: EXPERIMENTAL
Intervention: Randomized low-rank factorization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Truncated singular value decomposition
Number of subjects: 0
Study: 28152263

Group type: EXPERIMENTAL
Intervention: Good responders (>15% weight loss)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Fair responders (5%-10% weight loss)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Poor responders (<5% weight loss)
Number of subjects: 338
Study: 24240577

Group type: EXPERIMENTAL
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 29
Study: 22574166

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20177030

Group type: EXPERIMENTAL
Intervention: HEC-90 (trastuzumab plus cyclophosphamide and epirubicin 90 mg/m2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HEC-60 (trastuzumab plus cyclophosphamide and epirubicin 60 mg/m2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: EC-90 (epirubicin 90 mg/m2 and cyclophosphamide)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HEC-60
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HEC-90
Number of subjects: 120

Group type: COMPARATOR
Intervention: EC-90
Number of subjects: 120
Study: 18245119

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 5436
Study: 15774776

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy including fluorouracil and radiation
Number of subjects: 30
Study: 14692328

Group type: EXPERIMENTAL
Intervention: Yang Xue Qing Nao Granule (YXQNG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nimedipine plates
Number of subjects: 80
Study: 10386423

Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 'renal dose' (2.5‐4.0 microg/kg per min) for 48 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated controls (Group B)
Number of subjects: 40
Study: 8814216

Group type: EXPERIMENTAL
Intervention: 495 mg daily AA supplement (high AA group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5 mg/d of AA (low AA group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20 mg daily doses of hexadeuterated RRR‐alpha‐tocopherol acetate (d6‐alphaT)
Number of subjects: 20
Study: 1481636

Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 10
Study: 4026048

Group type: COMPARATOR
Intervention: Air
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxygen (40% O2)
Number of subjects: 8
Study: 31797581

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Data reduction techniques
Number of subjects: 146
Study: 29186416

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 1.4 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 2.8 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 4.6 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 6.8 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y 9.6 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 26901303

Group type: EXPERIMENTAL
Intervention: In-office bleaching combined with home bleaching (Technique 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home bleaching only (Technique 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-office bleaching (part of Technique 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home bleaching (part of Technique 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques (Technique 1 and Technique 2)
Number of subjects: 0
Study: 25072915

Group type: EXPERIMENTAL
Intervention: MFIA diagnoses of their lectures plus feedback by an expert observer after winter and summer semester lectures
Number of subjects: 21

Group type: COMPARATOR
Intervention: MFIA diagnoses only
Number of subjects: 21
Study: 22014699

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 20863369

Group type: EXPERIMENTAL
Intervention: Supervised exercises (SE)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 104
Study: 17352750

Group type: EXPERIMENTAL
Intervention: Adhesive drape, impermeable to water and air
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Water- and air-permeable absorbent dressing
Number of subjects: 1185
Study: 16286671

Group type: EXPERIMENTAL
Intervention: Astaxanthin (BioAstin; 1732 mg safflower oil; haematococcus algae extract [contains 4 mg astaxanthin and 480 mg lutein], n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1732 mg safflower oil, n = 10)
Number of subjects: 20
Study: 12075481

Group type: EXPERIMENTAL
Intervention: Tongue-stabilizing device (TSD)
Number of subjects: 6
Study: 10464888

Group type: COMPARATOR
Intervention: BDP-CFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDP-HFA
Number of subjects: 0
Study: 7564937

Group type: EXPERIMENTAL
Intervention: Videotape educational materials
Number of subjects: 82

Group type: COMPARATOR
Intervention: Booklet educational materials
Number of subjects: 82
Study: 1932903

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 44
Study: 6820075

Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 3.6% total nitrogen as arginine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 10.4% total nitrogen as arginine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Septic infants
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Other clinical parameters (birth weight, gestational age, oxygen requirements, enteral nutritional intake, congenital anomalies, heart disease)
Number of subjects: 26
Study: 31463257

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28893220

Group type: EXPERIMENTAL
Intervention: GUS-7 evaluation by a trainee rheumatologist (TR)
Number of subjects: 85

Group type: COMPARATOR
Intervention: GUS-7 evaluation by a senior rheumatologist (SR)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: GUS-7 usefulness rating by TR
Number of subjects: 85

Group type: COMPARATOR
Intervention: GUS-7 usefulness rating by SR
Number of subjects: 85
Study: 26821779

Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical stimulation (LMMS) - 10 minutes daily exposure at 30 Hz frequency, 0.3 g peak-to-peak acceleration.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (control group) - 10 minutes daily exposure, no mechanical stimulation.
Number of subjects: 138
Study: 24980023

Group type: EXPERIMENTAL
Intervention: Print-delivered basic (PB)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Print-delivered environmental (PE)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Web-based basic (WB)
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Web-based environmental (WE)
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2004
Study: 22709997

Group type: EXPERIMENTAL
Intervention: Fire prevention education delivered by on-duty firefighters through door-to-door visits
Number of subjects: 18473

Group type: COMPARATOR
Intervention: Cluster control group (no intervention)
Number of subjects: 18473
Study: 20231743

Group type: EXPERIMENTAL
Intervention: Menthol counterirritant (2 ml applied to anterior knee)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sham counterirritant (2 ml applied to anterior knee)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 18683490

Group type: EXPERIMENTAL
Intervention: Low-dose oral probucol (250 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probucol therapy for 7 days before and 6 months after coronary angioplasty
Number of subjects: 0
Study: 15865268

Group type: COMPARATOR
Intervention: Control group 1 (random)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group 2 (required clinical culture)
Number of subjects: 120
Study: 12060502

Group type: EXPERIMENTAL
Intervention: CPO/SA shampoo (1.5% ciclopirox olamine and 3% salicylic acid)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Nizoral (2.0% ketoconazole shampoo)
Number of subjects: 154
Study: 10212737

Group type: EXPERIMENTAL
Intervention: Febrile convulsion group (n=57)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Non-febrile illness group (n=66)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Social class differences
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 123
Study: 7818326

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (LA)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Lymph node sampling
Number of subjects: 182
Study: 2089092

Group type: EXPERIMENTAL
Intervention: MDL 72.974A (0.1-12 mg)
Number of subjects: 0
Study: 848665

Group type: COMPARATOR
Intervention: Intraluminal administration of 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramural administration of 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) therapy (general)
Number of subjects: 0
Study: 31744526

Group type: EXPERIMENTAL
Intervention: Listening to Mozart's Sonata for two pianos in D major (K.448) during cannulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: White noise during cannulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: No-sound period (wearing only headphones) during cannulation
Number of subjects: 120
Study: 28449281

Group type: EXPERIMENTAL
Intervention: 1 mg varenicline
Number of subjects: 484

Group type: COMPARATOR
Intervention: 0.5 mg varenicline
Number of subjects: 484
Study: 25847552

Group type: EXPERIMENTAL
Intervention: OMT+medication therapy
Number of subjects: 105
Study: 23818409

Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy (kid‐CIMT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intensive bimanual training
Number of subjects: 47
Study: 22008957

Group type: EXPERIMENTAL
Intervention: Formula A (0.04% DHA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Formula B (0.33% DHA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Formula C (0.52% DHA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Human Milk (HM) (0.51% AA, 0.38% DHA)
Number of subjects: 42
Study: 19755935

Group type: EXPERIMENTAL
Intervention: Posterolateral in situ fusion (PLF)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Posterolateral instrumented fusion with pedicle screws (PPS)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: PPS plus interbody fusion (360 degrees)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Decompression only without fusion
Number of subjects: 380
Study: 17323661

Group type: COMPARATOR
Intervention: Normal saline 0.1 ml/kg (Group NS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lignocaine 1.5 mg/kg (Group L)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg (Group R)
Number of subjects: 48
Study: 14745674

Group type: EXPERIMENTAL
Intervention: 5% cocaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine
Number of subjects: 50
Study: 11511427

Group type: EXPERIMENTAL
Intervention: Breath isoprene production in patients with CHF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Breath isoprene production in healthy control subjects
Number of subjects: 12
Study: 9591761

Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus and 12-hour infusion of 10 microg/min, EPIC regimen)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1), EPILOG regimen)
Number of subjects: 41
Study: 8201150

Group type: EXPERIMENTAL
Intervention: KC‐764 10 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: KC‐764 20 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: KC‐764 40 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: KC‐764 (all doses)
Number of subjects: 15
Study: 3310633

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g at night
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30742513

Group type: EXPERIMENTAL
Intervention: 2-hour simulation workshop using a medical foot-care model (n = 15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 2-hour workshop on compression therapy (n = 14)
Number of subjects: 29
Study: 28007137

Group type: EXPERIMENTAL
Intervention: HotBalloon ablation (HBA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 143
Study: 25552616

Group type: EXPERIMENTAL
Intervention: Facilitated access to a web-based brief intervention (BI) for risky drinkers delivered by primary healthcare professionals (PHCPs)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Face-to-face brief intervention (BI) by the practitioner
Number of subjects: 1000
Study: 20074288

Group type: EXPERIMENTAL
Intervention: Customized/wavefront guided ablation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 34
Study: 20646431

Group type: EXPERIMENTAL
Intervention: Nephrectomy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Radical Nephrectomy
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 134
Study: 17613282

Group type: EXPERIMENTAL
Intervention: MedDRA primary SOCs
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: ALIZE primary SOCs
Number of subjects: 355
Study: 15855919

Group type: EXPERIMENTAL
Intervention: Muscle electrostimulation (MEST)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 12585189

Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule (TXLC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Composite Danshen tablet
Number of subjects: 60
Study: 10516941

Group type: EXPERIMENTAL
Intervention: Ciclesonide nasal spray (200 micrograms per nostril)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7492160

Group type: EXPERIMENTAL
Intervention: Non-electrostatic spacer
Number of subjects: 124

Group type: COMPARATOR
Intervention: Babyhaler
Number of subjects: 124

Group type: COMPARATOR
Intervention: Nebuhaler
Number of subjects: 124

Group type: COMPARATOR
Intervention: AeroChamber
Number of subjects: 124
Study: 2038242

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive behavioral therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Therapist-based cognitive behavioral therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 36
Study: 7011011

Group type: EXPERIMENTAL
Intervention: Ibuprofen (Motrin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 14
Study: 30474504

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) - 30 Gy in 5 nonconsecutive fractions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole breast irradiation - 50 Gy in 25 fractions plus 10 Gy in 5 fractions to the tumor bed
Number of subjects: 22
Study: 28901831

Group type: EXPERIMENTAL
Intervention: Collaboration between traditional healers, faith healers, and biomedical care providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to collaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathways to better collaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shared sense of responsibility for patient well-being
Number of subjects: 0
Study: 24258063

Group type: EXPERIMENTAL
Intervention: Combined tutoring (standard and nonstandard equations)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Standard equations tutoring
Number of subjects: 51

Group type: COMPARATOR
Intervention: No-tutoring control
Number of subjects: 51
Study: 24183563

Group type: EXPERIMENTAL
Intervention: Pimavanserin 40 mg per day
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 199
Study: 22592354

Group type: EXPERIMENTAL
Intervention: Teach-to-goal (TTG): BI plus repeated demonstrations of inhaler use and participant comprehension assessments (teach-back)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brief intervention (BI): single-set of verbal and written step-by-step instructions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Teach-to-goal (TTG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brief intervention (BI)
Number of subjects: 50
Study: 19697196

Group type: EXPERIMENTAL
Intervention: TW+ (teams that received extra training in specific teamwork behaviours)
Number of subjects: 4

Group type: COMPARATOR
Intervention: TW- (teams that received only clinical training)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TW+
Number of subjects: 4

Group type: COMPARATOR
Intervention: TW-
Number of subjects: 4
Study: 17039354

Group type: EXPERIMENTAL
Intervention: Helmet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Facial mask
Number of subjects: 10
Study: 14694173

Group type: EXPERIMENTAL
Intervention: Postdialysis urea rebound measured using 30-min and 60-min postdialysis samples.
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: K/V as a predictor of rebound.
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Factors associated with greater rebound in patients using AV accesses or venous catheters.
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Equations of the form eKt/V = single‐pool Kt/V - B x (K/V).
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: Rate equation slope coefficients for K/V.
Number of subjects: 1245
Study: 11509518

Group type: EXPERIMENTAL
Intervention: Pharmacological melatonin levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Suppressed melatonin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal endogenous melatonin levels
Number of subjects: 16
Study: 9564797

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg total daily dose
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg total daily dose
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg total daily dose
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg total daily dose
Number of subjects: 473

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 473
Study: 8043333

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Atrioventricular pacing
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ventricular pacing
Number of subjects: 13
Study: 2500670

Group type: EXPERIMENTAL
Intervention: Enprostil 35-140 mcg (acute)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Enprostil 35 mcg or 70 mcg BID (chronic)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (chronic)
Number of subjects: 22
Study: 29264999

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both DCB and PTA
Number of subjects: 100
Study: 27776622

Group type: EXPERIMENTAL
Intervention: 12-week yoga intervention (n = 40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list (n = 20)
Number of subjects: 60
Study: 25382609

Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Number of subjects: 45
Study: 22784037

Group type: EXPERIMENTAL
Intervention: Once-daily tenofovir (TDF)
Number of subjects: 4747

Group type: EXPERIMENTAL
Intervention: Combination tenofovir‐emtricitabine (TDF‐FTC)
Number of subjects: 4747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4747
Study: 20410374

Group type: EXPERIMENTAL
Intervention: Clinician-assisted emotional disclosure (CAED)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 28